According to Zhitong Finance APP, DIAGENS-B (02526) jumped nearly 25% in morning trading. As of press time, the stock was up 20.08% at HK$288.2, with a turnover of HK$34.4798 million.

Northeast Securities released an update report on the AI industry chain during the National Day holiday period, noting that there were new developments on both the AI model and AI application sides, with AI4S (AI for Science) on the application side, particularly in pharmaceutical R&D, remaining especially active.

As a rare pure-play AI4S target in Hong Kong, DIAGENS-B has built a complete system spanning from data to models, from models to products, and from products to clinical applications. Public information shows that DIAGENS-B organizes real medical problems, imaging data, expert judgment, model training, evaluation, and application feedback into a single production chain. iMedLoop was launched on July 4, 2026, connecting data access, professional annotation, review and quality control, training and evaluation, deployment and release, and application feedback; iMedStudio supports AI pre-annotation, expert revision, multi-person result comparison, and dispute arbitration, and its related functions have been used in clinical research and internal R&D projects.